Advertisement

Fostamatinib for the treatment of chronic immune thrombocytopenia

Nathan T. Connell and Nancy Berliner

Abstract

Fostamatinib is a spleen tyrosine kinase (Syk) inhibitor recently approved for the treatment of chronic immune thrombocytopenia in patients without adequate response to at least one prior line of therapy. This article reviews the mechanism of action of fostamatinib and discusses the clinical safety and efficacy of fostamatinib in two industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.

  • Submitted November 19, 2018.
  • Accepted February 20, 2019.